Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Weighted Average) (2020 - 2025)

Apellis Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $126.1 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $126.1 million for Q4 2025, up 1.81% from a year ago — trailing twelve months through Dec 2025 was $126.1 million (up 1.81% YoY), and the annual figure for FY2025 was $126.1 million, up 1.81%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $126.1 million at Apellis Pharmaceuticals, roughly flat from $126.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for APLS hit a ceiling of $126.4 million in Q3 2025 and a floor of $80654.0 in Q2 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $117.2 million (2023), compared with a mean of $81.1 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 99.89% in 2021 and later skyrocketed 113818.06% in 2023.
  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $84.4 million in 2021, then increased by 25.7% to $106.1 million in 2022, then grew by 11.84% to $118.7 million in 2023, then rose by 4.4% to $123.9 million in 2024, then increased by 1.81% to $126.1 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $126.1 million (Q4 2025), $126.4 million (Q3 2025), and $126.0 million (Q2 2025) per Business Quant data.